EXEL

Exelixis Stock Price

24.50
0.77 (3.24%)
Upgrade to Real-Time
Regular Market
24.50
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Exelixis Inc EXEL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.77 3.24% 24.50 13:44:28
Close Price Low Price High Price Open Price Previous Close
23.70 24.69 23.80 23.73
Bid Price Ask Price Spread News
24.50 24.51 0.01 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,690 1,538,990 $ 23.99 $ 36,919,727 2,109,361 13.67 - 27.90
Last Trade Time Type Quantity Stock Price Currency
13:44:28 100 $ 24.50 USD

Exelixis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.57B 309.00M 273.25M $ 967.78M $ 271.94M 1.02 26.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Exelixis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EXEL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week26.1826.3022.9823.982,107,541-1.68-6.42%
1 Month22.1127.494419.8424.362,429,8752.3910.81%
3 Months22.7227.494419.8423.762,070,3301.787.83%
6 Months17.4027.9015.9523.312,789,3817.1040.8%
1 Year18.0727.9013.6720.322,983,9426.4335.58%
3 Years24.1832.5013.4221.373,213,2270.321.32%
5 Years5.6632.503.5517.363,788,19318.84332.86%

Exelixis Description

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.